Investments, Funding & Disinvestment

The company officially listed on the Hong Kong Stock Exchange on June 5, achieving a market valuation of approximately HK$10.7 billion (US$1.37 billion) following its debut.

Ascidian will lead target discovery and selected preclinical activities, while Lilly will oversee additional preclinical development, clinical research, manufacturing, regulatory activities, and global commercialization.

The agreement brings together Pfizer’s global expertise in clinical development, regulatory affairs, and commercialization with Innovent’s strengths in scientific discovery and early-stage oncology research.

The decision expands Imfinzi’s bladder cancer footprint beyond its earlier approval in muscle-invasive bladder cancer (MIBC), where it is used with chemotherapy agents’ gemcitabine and cisplatin before surgery and as a monotherapy afterward.

Under the deal, Blackstone Life Sciences will provide up to US$800 million in exchange for low- to mid-single-digit tiered royalties on future zumilokibart sales for 15 years.

The facility, which is expected to begin operations in 2027, will become Align Technology’s first manufacturing site in India and its fourth worldwide.

The initiative supports Moscow’s broader oncology modernization strategy, which combines investments in diagnostic technology, artificial intelligence, and clinician education to improve patient outcomes.

The ambitious project targets approximately 1.2 million residents, most of whom inhabit rural communities where traditional connectivity has remained inconsistent.

Health authorities estimate that approximately 20,000 babies are born with the condition each year, while nearly 30 percent of the population carries the sickle cell trait.

The acquisitions of Curevo, LimmaTech Biologics, and Vaccine Company mark the drugmaker’s eighth, ninth, and tenth deals of 2026 as it continues to diversify beyond its blockbuster obesity and diabetes franchises.